Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K, Tanaka C, Kanda M, Miyata K, Machida N, Sakai M, Kobayashi D, Teramoto H, Ishiyama A, Sato B, Oshima T, Kajikawa M, Matsushita H, Ishigure K, Yamashita K, Fujitake S, Sueoka S, Asada T, Shimizu D, Sugita S, Kuwatsuka Y, Maeda O, Furune S, Murotani K, Ando Y, Ebata T, Kodera Y.
Nakanishi K, et al. Among authors: kodera y.
Nagoya J Med Sci. 2024 Feb;86(1):43-51. doi: 10.18999/nagjms.86.1.43.
Nagoya J Med Sci. 2024.
PMID: 38505718
Free PMC article.